Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), has appointed Khandan Baradaran, PhD, as Senior Vice President of Regulatory and Quality.
 
Baradaran brings nearly two decades of experience in manufacturing and regulatory review of gene therapy products, including regulatory and chemistry, manufacturing, and controls (CMC) experience.
 
“Khandan’s experience leading quality and compliance for rare genetic disease biopharmaceutical companies will be valuable as we continue to advance our versatile MCO platform, including MCO-010, which is driving our expanding pipeline of programs. This appointment supports the continued advancement of our mutation-agnostic therapies to restore vision in millions of people blinded by retinal diseases and further highlights our continued growth as a company,” said Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope.
 
“I am honored to join the highly motivated team at Nanoscope in the development of its novel approach to treating retinal degenerative diseases,” said Baradaran. “Following the impressive durable efficacy and safety results from the randomized control trial in retinitis pigmentosa, I eagerly anticipate contributing to Nanoscope’s advancement as we navigate forthcoming regulatory milestones and prepare for commercial readiness.”

Experience

Baradaran was most recently Vice President of Regulatory CMC at Ultragenyx Pharmaceutical Inc., a biopharmaceutical company involved in the research and development of novel products for the treatment of rare and ultra-rare genetic diseases.
 
Previously, she was Vice President and Head of Quality at Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Prior to this, she held CMC and Regulatory positions at Biogen, Novartis, and Dyax.
 
Baradaran holds a PhD in Virology from Harvard University and a BA in Molecular Biology from Wellesley College.